To evaluate the long-term outcomes for prostate cancer (PCa) patients with lymph node involvement (LNI) treated with radiotherapy at the University of California San Francisco.
I
f lymph node involvement (LNI) is present in most cancers, radiotherapy plays a major role in improving locoregional control as well as disease-specific survival. Over several decades, many assumed that prostate cancer (PCa) was different from other cancers and believed that the presence of LNI was indicative of systemic disease that did not benefit from regional therapy. However, Radiation Therapy Oncology Group 9413 demonstrated that there might be a therapeutic advantage to nodal pelvic irradiation for PCa patients at high risk of occult nodal disease. 1 In the American Joint Committee on Cancer staging system, patients with LNI are considered as having metastatic disease. Nevertheless, if hormonal therapy (HT) alone is given, these patients are more likely to have a local failure, whereas if they undergo local treatment only, they are more likely to develop distant metastases. 2 Surgery, radiation therapy (RT), and HT (when each is used alone), have proved disappointing as potentially curative strategies for node-positive PCa. [2] [3] [4] [5] [6] [7] [8] [9] Several studies have reported limited overall survival (OS) benefit of radical prostatectomy (RP) combined with adjuvant androgen deprivation when compared with androgen deprivation alone. 5, [10] [11] [12] [13] [14] Similarly, several studies describing exclusive radiotherapy (eRT) have reported a trend toward an improvement in longterm outcomes when androgen deprivation therapy was included. [15] [16] [17] [18] These results prompted us to retrospectively review the long-term outcomes of PCa patients with lymph node involvement (PCa-LNI) undergoing eRT or RP plus postoperative radiotherapy at the University of California San Francisco.
MATERIALS AND METHODS

Patient Selection
It has been the policy at University of California San Francisco to offer radiotherapy to newly diagnosed (PCa-LNI) and no evidence of distant metastasis. Pelvic LNI was identified in 3 ways: (1) as an incidental finding on radiographic evidence of an LNI (computed tomography or magnetic resonance imaging with a round axis >10 mm); (2) as the result of surgical lymph node staging performed in patients with high-risk features; or (3) after RP and pelvic lymph node dissection.
Our institutional review board approved and waived the informed consent requirement for this retrospective review of the data of 91 PCa-LNI patients with at least 1 prostate-specific antigen (PSA) value in their FU and who were treated between 1988 and 2009. All patients were treated with radiotherapy in one of the following ways: (1) eRT; (2) RP followed by external beam adjuvant radiotherapy (aRT); and (3) RP followed by external beam salvage radiotherapy (sRT). For this analysis, patients treated with postoperative radiotherapy were dichotomized according to the duration between RP and the first day of radiotherapy: aRT is defined as r6 months and sRT defined as >6 months indicating disease recurrence.
Endpoints
Biochemical control with no evidence of disease (bNED) was defined as the time interval between the first day of radiotherapy and biochemical failure. Biochemical failure was defined as an increase in PSA measurement of 2 ng/mL above the observed nadir (Phoenix definition 19 ) for eRT patients or an increase in PSA > 1.0 ng/mL for patients previously treated with RP. We chose to use this definition for failure which was specifically evaluated in patients treated with RP followed by postoperative RT because it is more likely to reflect "clinically significant" failure. 20 OS was defined as the time interval between the start of primary treatment for PCa (RP or radiotherapy) and death due to any cause or last FU if still alive. Cause-specific survival (CSS) was defined as the time interval between the start of primary treatment (RP or radiotherapy) and death from PCa. Disease-free survival (DFS) was defined as the time interval between the first day of radiotherapy and biochemical failure, clinical local or regional failure, distant failure, a second cancer, or death. Patients receiving radiotherapy as sRT after RP will have already failed so only the benefit of radiotherapy after failure is presented for this subset. Therefore, when evaluating bNED and DFS, the durations for all 3 treatment groups started from the date RT began.
Statistics
Comparability of patient and disease characteristics at diagnosis among the 3 treatment groups were evaluated using analysis of variance methods with the pairwise Newman-Keuls post hoc tests for continuous variables, the nonparametric Kruskal-Wallis test for distributions, and the w 2 test or Fisher exact test for categorical variables.
For the 3 treatment groups the probability distributions of time to failure for OS and CSS measured from the start of curative treatment and for DFS and bNED measured from the end of RT were estimated using the Kaplan-Meier product limit method with subsets compared using the log rank test. Point estimates were obtained from these distributions. Univariate analyses of patient and disease features to identify predictors of OS and bNED outcomes were performed using Cox proportional hazards model. Analyses to identify predictors of CSS or DFS were not carried out due to differences among the treatment subsets in terms of reasons for radiotherapy (before or possibly after first recurrence), the low frequency of death due to PCa, and differing FU durations. Multivariate analysis was performed using Cox proportional hazards model with a forward stepwise procedure to identify independent predictors of bNED and OS. Multivariate analyses were performed to summarize OS and bNED results using different patient groupings. The patient subsets that were evaluated to identify predictors of OS were (1) the total sample of patients with LNI; (2) patients treated with RT as part of primary therapy (eRT plus aRT); and (3) patients who had a RP (aRT plus sRT). Only the first 2 patient groups were analyzed to identify predictors of bNED. Because the sRT group could be given RT after a first recurrence, evaluation of biochemical control was not considered comparable with those who received aRT. All statistical analyses were performed using Statistica version 6.0 (StatSoft Inc.) or Stata version 8.0 (Stata Corp.).
RESULTS
Patient and Treatment Characteristics
Thirty-five patients were treated with eRT (38%). Among patients treated with RP, 18 patients were treated with aRT and 38 patients with sRT. The mean age overall at start of initial treatment for PCa was 62.9 ± 8.8 years. Patients who had undergone a RP before RT were significantly younger than patients treated with eRT (post hoc tests: eRT vs. aRT: P = 0.005; eRT vs. sRT: P = 0.002). The median Gleason score (GS) for the entire patient cohort was 7 (range, 3 to 10). Overall, there was no significant difference in GS distribution among the treatment groups (P = 0.08) although patients treated with aRT at the time of surgery had a GS > 7 more often (71% vs. 47% with eRT and 34% with sRT: P = 0.04).
Overall the median pretreatment maximal PSA level was 12.9 ng/mL range, 0.3 to >100 ng/mL). There was a significant difference in pretreatment PSA level between those who had a RP before radiotherapy and those who did not (P = 0.0001). Patients treated with eRT were more likely to have a pretherapeutic PSA level of Z20.0 ng/mL (56% vs. 13% in each of the 2 groups treated initially with a RP). Although any comparison of the T-stage distributions between eRT patients (ie, clinical) and RP patients (ie, pathologic) should be interpreted with caution, as there was no significant difference between these 2 groups of patients (P = 0.27).
In summary, this represents a high-risk cohort with 79% of the patients displaying at least 1 high-risk feature (GSZ8, PSAZ20 ng/mL, or T3-T4 stage disease). High-risk patients were more often treated with radiotherapy as part of their primary treatment more often (eRT: 89% were high risk, aRT: 94%, and sRT: 63%; P = 0.01). The median duration between RP and radiotherapy was 3.8 months (range, 1.6 to 5.7 mo) for the aRT group and 11.0 months (range, 6.1 to 190 mo) for the sRT group. The range of RT doses delivered over the 20-year period of time reflects the changes in practice patterns as conventional radiotherapy gave way to 3-dimensional conformal and then to intensity-modulated radiotherapy.
The duration of radiotherapy was not statistically different among the 3 groups with medians of 57 days for the eRT group, 50 days for the aRT group, and 52 days for the sRT group (P = 0.13). Eighty-two percent of the entire study sample was treated with hormone therapy with similar proportions across treatment subsets (P = 0.83). For this report, the median FU for the entire study cohort from the start of initial treatment for PCa was 69.2 months. It was significantly shorter for patients treated with aRT (41.8 mo) compared with patients treated with eRT and sRT (median, 64.7 and 86.0 mo, respectively) (P = 0.01). Recall that the sRT patients had at least 6 months of FU after RP before starting their radiotherapy. When considering the entire cohort the median FU was 55.3 months from the start of radiotherapy and again there was a statistically significant difference among the 3 subsets (P = 0.02) reflecting the shorter duration for those treated with aRT with a median of 36.7 months ranging from 2 to 81 months. The median duration was 64.7 months for the eRT group as this was the primary therapy and 52.9 months for the sRT group.
Long-term Outcomes
At the last FU, 56 of the 91 patients were still alive and disease free. Among patients still alive and disease free at the time of this analysis, the median FU from the start of RT was 49.2 months for those in the eRT group (n = 13), 33.0 months in the aRT group (n = 14), and 66.8 months in the sRT group (n = 29) (P = 0.18). The median last observed PSA value for these surviving recurrence-free patients was 0.05 ng/mL (minimum = 0 to maximum = 1.01). The median PSA value in each of the 3 groups was 0.16 ng/mL (minimum = 0.01 to maximum = 1.01) in eRT, 0.04 ng/mL (minimum = 0.01 to maximum = 0.13) in aRT, and 0.02 (minimum = 0 to maximum = 0.55) in sRT. The distribution of the last PSA values observed displayed by the time of last FU after RT for each treatment arm for patients alive and disease free is in Figure 1 .
At the time of the analysis, the overall 5-year estimate of bNED from the start of RT was 68% (95% confidence interval [CI], 56%-79%). There was a borderline statistical difference in the rate of biochemical failure among the 3 groups (5 y estimates: 60% [95% CI, 40%-75%] for the eRT group, 70% [95% CI, 35%-88%] for the aRT group, and 79% [95% CI, 58%-90%] for the sRT group) (log rank: P = 0.09) (Fig. 2) . The 5-year DFS estimate calculated from the start of RT was 67% (95% CI, 54%-77%) with no difference among the 3 RT regimens with 58% for the eRT group, 70% for the aRT group, and 76% for the sRT group (log rank: P = 0.24).
The 10-year estimate of OS from primary therapy for the entire study cohort was 78% (95% CI, 62%-88%). Again, there was a borderline statistical difference in OS among the 3 treatment groups (log rank: P = 0.06) (Fig. 3) . The 10-year estimates of OS were 70% for the eRT group of patients and 90% for the sRT group. OS ranged from 6.5 to 86.4 months for the aRT subset. There were 19 patients surviving at least 10 years, 10 treated with eRT and 9 with sRT. Among the 20 patients who have died as of this analysis 7 were due to PCa and 2 of the 7 had recurred biochemically after RT. The overall CSS 10-year estimate was 89% (95% CI, 78%-95%). There was no difference among the 3 treatment groups (log rank: P = 0.57) and the 10-year estimate of CSS was 86% for the eRT group and 93% for the sRT group.
There was no significant difference in biochemical control following RT between patients treated with neoadjuvant and/or adjuvant HT and patients treated without HT (5-y estimates: 68% vs. 64%, respectively; log rank: P = 0.38). Overall there was a significant improvement in DFS for patients treated with HT when evaluated from the start of RT (5-y estimates: 67% vs. 60%; log rank: P = 0.04). Figure 4 displays OS with and without hormone therapy. OS was significantly prolonged for patients treated with HT (10-y estimates: 82% vs. 66%: log rank: P = 0.001). The frequency of death due to PCa was low and there was no difference with and without HT in CSS (log rank: P = 0.67) (10-y estimates were 90% and 87%, respectively).
Predictive Factors
Univariate analysis using Cox proportional hazards model indicated that patients with a GSZ8 had a significantly shorter bNED (P = 0.01) as well as a shorter OS (P = 0.02). Further analyses of the roles of a high GS (8 to 10) and high pretreatment PSA ( > 20 ng/mL) as predictors of shorter OS indicated that each factor was a significant predictor when limited to those patients who started radiotherapy immediately either as primary treatment (eRT) or adjuvantly following RP (P = 0.02 and 0.04, respectively). Overall significant improvement in biochemical control for patients with a GSr7 reflects the benefit for patients who had a RP (aRT or sRT) (P = 0.03) but not among those who did not (P = 0.24). In addition, age (at start of any treatment or at start of radiotherapy) was also a significant predictor of both OS and bNED. It was determined that younger aged patients at the time of FIGURE 1. Distribution of the last prostate-specific antigen value by treatment arm for patients alive and disease free (n = 56). aRT indicates adjuvant radiotherapy; eRT, exclusive radiotherapy; sRT, salvage radiotherapy. FIGURE 2. Estimated probability distribution of biochemical control measured from the start of radiotherapy with respect to the treatment arm (n = 91). aRT indicates adjuvant radiotherapy; eRT, exclusive radiotherapy; sRT, salvage radiotherapy. radiotherapy had significantly longer biochemical control if they were treated immediately with radiotherapy, either eRT or aRT (P = 0.01). Age (at start of any treatment or at start of radiotherapy) was not a predictor among those who received RT as salvage. Patients treated with combined RT and HT had improved OS in comparison with patients treated without HT (P = 0.009). This improvement reflects the difference due to HT for patients who had a RP (P = 0.01) and is not a significant predictor of OS among those treated with radiotherapy as primary therapy (P = 0.68).
Patients treated with RP had better OS (P = 0.03) and better bNED (P = 0.05) in comparison with patients treated without RP. This effect due to RP is not observed when limited to the eRT and aRT subsets, which reduces the impact of any extended delay in starting radiotherapy (P = 0.96 and 0.80, respectively). Results from the univariate analysis of prognostic factors on OS and bNED are summarized in Table 1 .
Because of the differing univariate results reflecting when radiotherapy started or whether the patient had a RP, 3 multivariate analyses were performed for 3 different subsets of patients to identify independent predictors of OS and bNED. Using Cox proportional hazards model with a forward stepwise approach, the analysis of the entire patient sample indicated that being younger at the start of treatment for PCa was the most significant predictor prolonging OS (likelihood ratio [LLR] test: P = 0.002) followed by having a GSr7 (LLR test: P = 0.01). When limited to patients who received radiotherapy as their primary therapy (eRT plus aRT) the same 2 factors were significant independent predictors of OS (LLR tests: age: P = 0.046, GSr7 vs. >7: P = 0.03).
When OS was evaluated among all patients who had a RP, being treated with HT was the most significant predictor prolonging OS (LLR test: P = 0.02) as well as being younger at the start of treatment (LLR test: P = 0.03) ( Table 2 ). For the full patient sample the same 2 features that were predictors of OS, GS (r7 vs. >7) and then age determined at radiotherapy, were significant independent predictors of biochemical control (LLR tests: P = 0.01 and 0.02, respectively).
When limited to those who received radiotherapy as their primary therapy (eRT plus aRT), again the same 2 variables were significant predictors but in the reverse order of importance. The LLR test for this final model is 0.016. The timing of radiotherapy (alone, as aRT or sRT) for patients with LNI at baseline is not an independent predictor of OS or bNED for any of the models considered.
DISCUSSION
There has been a great controversy over what constitutes the appropriate management for PCa patients harboring metastatic lymph nodes. Because androgen-independent clones will inevitably occur over time only with HT treatment, combining an effective treatment targeted to both androgendependent and androgen-independent disease with a curative intent is needed. Significance is determined by the likelihood ratio test. T stage, even when limited to patients who had a RP, and pPSA as a continuous variable were not significant predictors for either OS or biochemical control. aRT indicates adjuvant radiotherapy; bNED, biochemically no evidence of disease; CI, confidence interval; eRT, exclusive external radiotherapy; PSA, prostatespecific antigen; sRT, salvage radiotherapy.
Although the 5-year OS estimate was roughly 70% with immediate Androgen Deprivation Therapy after pelvic lymphadenectomy (without RP) for PCa patients with LNI, 21 this rate was 20% higher when combining RP. 22 These large differences in OS suggest that local treatment influences survival despite the presence of LNI. These results are supported by a recent observational study which showed a positive impact on OS of RP for LN-positive PCa patients when compared with patients treated without RP (84% vs. 60% at 5 y). 23 In this study 75% of patients underwent adjuvant HT and 25% adjuvant radiation, so interactions between these treatments could explain the good outcomes that were observed.
A large retrospective study has questioned the value of HT alone in patients treated with RP in the context of LNI. However, patients treated with postoperative RT appear to be more likely to have better biochemical recurrence-free survival (HR = 0.49, P = 0.002) and PCa-specific survival (HR = 0.38, P = 0.009) in comparison with patients treated with adjuvant hormones alone. 24 Mapping of lymph nodal involvement with evolving modern imaging as well as surgical techniques showed that the likelihood of having metastatic nodes outside the fields of an extensive pelvic lymph node dissection remains substantial, [25] [26] [27] thus raising questions about the potential limitations of extensive pelvic lymph node dissection alone compared with RT with extended pelvic fields. Moreover, for older patients and/or patients with a high tumor burden (clinical bulky nodes or multiple regional LN at diagnosis and/or significant extracapsular extension of the primary tumor), surgeons are commonly more reluctant to consider those patients for RP.
Several other studies appear to be supportive of our findings. For example, with eRT, Zagars et al 28 showed in a large retrospective study that combining HT with radiotherapy significantly decreases 10-year local failure, distant failure, and OS rates when compared with HT alone (67% vs. 46% alive at 10 y). We found on multivariate analysis that the significant independent predictors of a poorer OS and bNED were being older and having a GSZ8. These results are in line with most of the published series on eRT which found that age and GS were stronger predictors for OS. 16, 18, 28, 29 In the subset analysis of pN1 patients in the Radiation Therapy Oncology Group 85-31 trial, combining HT with RT also had a significantly favorable impact on all the endpoints using multivariate analysis, and patients treated with RP had a lower rate of distant metastatic failures and progression-free survival. 16 We also found that patients treated with RT combined with HT were more likely to be alive after 10 years (82% vs. 66% in our study, P = 0.001).
Despite the strengths of our study, such as the availability of clinical and pathologic characteristics, the extensive PSA FU and the high proportion of patients who received HT in each group of patients, our study suffered from some limitations. Major limitations arise from the retrospective study design, with drawbacks being related to patient selection bias, the lack of clinical characteristics of nodal involvement (number of nodes invaded with respect to each treatment group analyzed, presence of extracapsular extension in the nodes). Patients with LNI selected at baseline for eRT combined with hormones are more likely to have a higher tumoral burden, thus explaining why they did not undergo surgery. Nevertheless, although patients in the eRT group in our study were more likely to be older (median age at start of radiotherapy: 67 y) and to have a higher GS (47%Z8) or higher baseline PSA values (56%Z20 ng/mL), overall we found no statistical differences for all disease endpoints among the 3 groups of patients (eRT vs. RP followed by aRT vs. RP followed by sRT). Our results strengthen the need for a randomized trial for cN1 and/or pN1 trial, testing the place of radiotherapy with or without RP. Significant predictors are listed in the order of importance based upon the likelihood ratio (LLR) test. The hazard ratio with a 95% confidence interval (CI) and the probability from test of the parameter being equal to 1 (no difference) are indicated for predictors of overall survival and biochemical control.
*Univariate analysis identified age at the start of all treatment (P = 0.003), age at the start of RT (P = 0.01), GS ( r7 vs. >7) (P = 0.01) and having a RP (P = 0.05) as predictors of biochemical control. The probability for the LLR test for the final model when limited to those treated immediately with RT is 0.016.
aRT indicates adjuvant radiotherapy; CI, confidence interval; eRT, exclusive external radiotherapy; GS, Gleason score; HT, hormonal therapy; LLR, likelihood ratio; RP, radical prostatectomy; sRT, salvage radiotherapy.
